AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15506570 — intervention group
Group type: COMPARATOR
Intervention: CAGE screening approach
Number of subjects: 2800
Study 11723348 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail/web-based survey
Number of subjects: 114
Study 11723348 — intervention group
Group type: COMPARATOR
Intervention: Conventional postal mail survey
Number of subjects: 114
Study 9552949 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 868
Study 9552949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study 7917911 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon α(2b) (IFN‐α(2b))
Number of subjects: 29
Study 7917911 — intervention group
Group type: COMPARATOR
Intervention: Normal donors
Number of subjects: 29
Study 2498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regimen of propranolol (4 or 3 times daily)
Number of subjects: 48
Study 2498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent regimen of propranolol (twice daily)
Number of subjects: 48
Study 2498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol used for 12 weeks
Number of subjects: 48
Study 2498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily regimen of propranolol
Number of subjects: 48
Study 2498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher daily doses of propranolol
Number of subjects: 48
Study 31216205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0
Study 31216205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27930613 — intervention group
Group type: EXPERIMENTAL
Intervention: Community empowerment-based combination HIV prevention model (Project Shikamana)
Number of subjects: 496
Study 26231305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg administered monthly
Number of subjects: 500
Study 26231305 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab 0.5 mg administered as needed (PRN) after 3 monthly loading doses
Number of subjects: 500
Study 24597260 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled lumbar epidural combined anesthesia with Doula using ropivacaine and sufentanil
Number of subjects: 200
Study 24597260 — intervention group
Group type: COMPARATOR
Intervention: Control group without any analgesic measurements
Number of subjects: 200
Study 21406193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (100 mg/day)
Number of subjects: 66
Study 21406193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone (100 mg/day)
Number of subjects: 66
Study 21406193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 18192835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined consumption of red wine and green olive oil (RO)
Number of subjects: 15
Study 18192835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined consumption of red wine and refined olive oil (RG)
Number of subjects: 15
Study 18192835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined consumption of white wine and olive oil (WO)
Number of subjects: 15
Study 18192835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined consumption of white wine and green olive oil (WG)
Number of subjects: 15
Study 18192835 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 15
Study 18192835 — intervention group
Group type: EXPERIMENTAL
Intervention: All four combinations of wine and olive oil
Number of subjects: 15
Study 16645234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostable autologous hemoderivative
Number of subjects: 101
Study 16645234 — intervention group
Group type: COMPARATOR
Intervention: Adequate control measures
Number of subjects: 101
Study 14662586 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with ablation of the avascular retina
Number of subjects: 317
Study 14662586 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control eye)
Number of subjects: 317
Study 10960936 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback training of center‐of‐gravity (CoG) positioning
Number of subjects: 46
Study 10960936 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Number of subjects: 46
Study 10960936 — intervention group
Group type: COMPARATOR
Intervention: Regular therapy (physical therapy and occupational therapy)
Number of subjects: 46
Study 8792754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 416
Study 8792754 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 416
Study 8792754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 1467105 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop computer control of an infusion of a 5:1 mixture of trimetaphan camsylate (TMP) and sodium nitroprusside (SNP)
Number of subjects: 20
Study 1467105 — intervention group
Group type: COMPARATOR
Intervention: Manual control by an experienced anaesthetist
Number of subjects: 20
Study 6086866 — intervention group
Group type: EXPERIMENTAL
Intervention: VZIG (standard doses)
Number of subjects: 13
Study 6086866 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV at 4 ml/kg every 4 weeks for four doses
Number of subjects: 13
Study 6086866 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV at 6 ml/kg every 6 weeks for two to four doses
Number of subjects: 13
Study 6086866 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV at 4 ml/kg
Number of subjects: 13
Study 6086866 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV at 6 ml/kg
Number of subjects: 13
Study 6086866 — intervention group
Group type: COMPARATOR
Intervention: VZIG or IGIV
Number of subjects: 13
Study 30922731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab (20 mg oral lenvatinib daily plus 200 mg intravenous pembrolizumab every 3 weeks)
Number of subjects: 54
Study 30922731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 54
Study 29351895 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Parenting (PiP) program
Number of subjects: 359
Study 29351895 — intervention group
Group type: COMPARATOR
Intervention: Standardized package of five Web‐based factsheets about adolescent development and well‐being (active-control)
Number of subjects: 359
Study 26488145 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis group (aspiration before hyaluronan injection)
Number of subjects: 180
Study 26488145 — intervention group
Group type: COMPARATOR
Intervention: Nonarthrocentesis group (no aspiration before hyaluronan injection)
Number of subjects: 180
Study 26488145 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and investigator assessment of effectiveness
Number of subjects: 180
Study 23146963 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural processes associated with stimulus encoding and maintenance in the lateral prefrontal cortex (PFC)
Number of subjects: 0
Study 23146963 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural connectivity between lateral PFC and extrastriate cortex
Number of subjects: 0
Study 22158146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load high-velocity (LLHV = 6 sets of 12 reps at 35% 1RM)
Number of subjects: 12
Study 22158146 — intervention group
Group type: COMPARATOR
Intervention: High load-low velocity (HLLV = 3 sets of 12 reps at 70% 1RM)
Number of subjects: 12
Study 22158146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load high-velocity (LLHV)
Number of subjects: 12
Study 22158146 — intervention group
Group type: COMPARATOR
Intervention: High load-low velocity (HLLV)
Number of subjects: 12
Study 20362976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) based on exposure and mindfulness exercises delivered via the Internet.
Number of subjects: 85
Study 20362976 — intervention group
Group type: COMPARATOR
Intervention: Online discussion forum (control condition).
Number of subjects: 85
Study 18847622 — intervention group
Group type: EXPERIMENTAL
Intervention: School nurse supervision of glucose and insulin-dose adjustment (3-month intervention)
Number of subjects: 36
Study 16212578 — intervention group
Group type: EXPERIMENTAL
Intervention: sub-antimicrobial doxycycline (20 mg, bid)
Number of subjects: 69
Study 16212578 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 69
Study 11840077 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard titer (50% tissue culture‐infective dose, 103.8) Schwarz measles vaccine after meningococcal vaccine
Number of subjects: 510
Study 11840077 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased titer (10(4.7) PFU) Edmonston‐Zagreb measles vaccine followed by meningococcal vaccine
Number of subjects: 510
Study 11840077 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased titer (10(4.7) PFU) Connaught vaccine followed by standard titer Schwarz measles vaccine
Number of subjects: 510
Study 11840077 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 510
Study 10405190 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset IVH
Number of subjects: 440
Study 10405190 — intervention group
Group type: COMPARATOR
Intervention: No early-onset IVH
Number of subjects: 440
Study 7496419 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 1 (specific underwear); 3 couples, 42 cycles
Number of subjects: 9
Study 7496419 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 (supplementary ring with specific underwear); 6 couples, 117 cycles
Number of subjects: 9
Study 1981019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg alone
Number of subjects: 10
Study 1981019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg with rifampicin 600 mg once daily
Number of subjects: 10
Study 1981019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg with ranitidine 150 mg twice daily
Number of subjects: 10
Study 7018306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 7018306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31888358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 400
Study 31888358 — intervention group
Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty
Number of subjects: 400
Study 31888358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study 31185906 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral paracetamol
Number of subjects: 324
Study 31185906 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg oral paracetamol
Number of subjects: 324
Study 31185906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 29178757 — intervention group
Group type: EXPERIMENTAL
Intervention: White MTA
Number of subjects: 129
Study 29178757 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 129
Study 26194675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFRT)
Number of subjects: 137
Study 26194675 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation therapy (STRT)
Number of subjects: 137
Study 23375177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring relationship quality
Number of subjects: 526
Study 23375177 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quality relationships with parents and teachers
Number of subjects: 526
Study 23375177 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect sizes of associations
Number of subjects: 526
Study 20708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg (slow-release)
Number of subjects: 22
Study 20708287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19213787 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg intravenously)
Number of subjects: 17
Study 19213787 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 17
Study 16824149 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg on days 0 and 4)
Number of subjects: 58
Study 16824149 — intervention group
Group type: COMPARATOR
Intervention: Daclizumab (50 mg on days 1 and 14)
Number of subjects: 58
Study 12615254 — intervention group
Group type: EXPERIMENTAL
Intervention: RV infarction
Number of subjects: 25
Study 12615254 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe RV infarction (right atrial pressure ≥ 15 mm Hg)
Number of subjects: 25
Study 12615254 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild/moderate RV infarction (right atrial pressure < 15 mm Hg)
Number of subjects: 25
Study 10831476 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment of bipolar I disorder with anxiety symptoms
Number of subjects: 124
Study 10831476 — intervention group
Group type: COMPARATOR
Intervention: Acute treatment of bipolar I disorder without anxiety symptoms
Number of subjects: 124
Study 9118516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (epoprostenol) infusion for 12 weeks in addition to conventional therapy (n = 41)
Number of subjects: 81
Study 9118516 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone for 12 weeks (n = 40)
Number of subjects: 81
Study 8472628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GL‐G injection (intramuscularly)
Number of subjects: 38
Study 8472628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GL‐G injection (intravenously)
Number of subjects: 38
Study 8472628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GL‐G injection
Number of subjects: 38
Study 3525176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (ID-MTX) and prednisone (PRED)
Number of subjects: 137
Study 3525176 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (VCR) and prednisone (PRED)
Number of subjects: 137
Study 31936495 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophysical therapy
Number of subjects: 24
Study 31936495 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 29570546 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) sessions
Number of subjects: 163
Study 29570546 — intervention group
Group type: COMPARATOR
Intervention: Control (standard medical care)
Number of subjects: 163
Study 26702030 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (5 interviews over 12 months)
Number of subjects: 372
Study 26702030 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 372
Study 24726166 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with optimal medical therapy
Number of subjects: 2201
Study 24726166 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone (MED)
Number of subjects: 2201
Study 24726166 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfarction (universal definition)
Number of subjects: 2201
Study 24726166 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfarction (OAT criteria)
Number of subjects: 2201
Study 24726166 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfarction occurring within 6 months
Number of subjects: 2201
Study 24726166 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfarction due to the same IRA and a different epicardial vessel
Number of subjects: 2201
Study 23276779 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 60
Study 23276779 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 60
Study 20576158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid training for teachers
Number of subjects: 14
Study 20576158 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 14
Study 18753099 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (n = 60)
Number of subjects: 120
Study 18753099 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (n = 60)
Number of subjects: 120
Study 16698134 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg/day as a single dose)
Number of subjects: 20
Study 16698134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vegetable-based)
Number of subjects: 20
Study 16698134 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg/day)
Number of subjects: 20
Study 15133864 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine sodium
Number of subjects: 102
Study 15133864 — intervention group
Group type: COMPARATOR
Intervention: SASP
Number of subjects: 102
Study 15133864 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartleaf houttuynia herb
Number of subjects: 102
Study 15133864 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangshuanling
Number of subjects: 102
Study 15133864 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 102
Study 11575648 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep Pap Test (TP)
Number of subjects: 1999
Study 11575648 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap Test (CV)
Number of subjects: 1999
Study 9777477 — intervention group
Group type: EXPERIMENTAL
Intervention: Air scented with peppermint
Number of subjects: 0
Study 9777477 — intervention group
Group type: COMPARATOR
Intervention: Unscented air
Number of subjects: 0
Study 8143832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin, 50 mg t.d.s. for 3 days
Number of subjects: 12
Study 8143832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3284341 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 105
Study 3284341 — intervention group
Group type: COMPARATOR
Intervention: prazosin
Number of subjects: 105
Study 28480984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chondroitin sulfate (CS)
Number of subjects: 42
Study 28480984 — intervention group
Group type: COMPARATOR
Intervention: Intravesical hyaluronic acid (HA)
Number of subjects: 42
Study 26609122 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused (TF) treatment (8 sessions prolonged exposure or eye movement desensitization)
Number of subjects: 155
Study 26609122 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 155
Study 25623237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing removed on the first postoperative day
Number of subjects: 96
Study 25623237 — intervention group
Group type: COMPARATOR
Intervention: Dressing removed on the sixth postoperative day
Number of subjects: 96
Study 24384734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 315
Study 24384734 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 315
Study 21911136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (54 patients, group D) plus cyclosporine (CsA), mycophenolate mofetil and steroids
Number of subjects: 103
Study 21911136 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (55 patients, group T) plus cyclosporine (CsA), mycophenolate mofetil and steroids
Number of subjects: 103
Study 21911136 — intervention group
Group type: COMPARATOR
Intervention: CMVi+ group
Number of subjects: 103
Study 21911136 — intervention group
Group type: COMPARATOR
Intervention: CMVi‐ group
Number of subjects: 103
Study 18715238 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced web-based behavioral smokeless tobacco cessation intervention
Number of subjects: 402
Study 18715238 — intervention group
Group type: COMPARATOR
Intervention: Basic information-only control condition
Number of subjects: 402
Study 16966688 — intervention group
Group type: EXPERIMENTAL
Intervention: oblimersen sodium plus dacarbazine (1,000 mg/m2)
Number of subjects: 771
Study 14767414 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized psychomotor fitness program (PF)
Number of subjects: 141
Study 14767414 — intervention group
Group type: COMPARATOR
Intervention: General program of psychomotor therapy (GPMT)
Number of subjects: 141
Study 11103113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 84
Study 11103113 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine plus 0.0002% fentanyl
Number of subjects: 84
Study 11517472 — intervention group
Group type: EXPERIMENTAL
Intervention: Semax (12 mg for moderate severity, 18 mg for severe strokes, treatment course of 5 to 10 days)
Number of subjects: 30
Study 11517472 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 30
Study 8474482 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 10 micrograms/kg
Number of subjects: 37
Study 8474482 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 50 micrograms/kg
Number of subjects: 37
Study 8474482 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 100 micrograms/kg
Number of subjects: 37
Study 8474482 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy after apomorphine test
Number of subjects: 37
Study 8474482 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis based on clinical evaluation and levodopa response
Number of subjects: 37
Study 8474482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3779035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g doses four times a day for 2 days prior to and during the study)
Number of subjects: 12
Study 3779035 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg single oral dose)
Number of subjects: 12
Study 31687738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookah is the Enemy of Health Campaign (HEHC)
Number of subjects: 280
Study 31687738 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 280
Study 28714788 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Oscillation Therapy (DOT)
Number of subjects: 29
Study 28054902 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel goal-directed hemodynamic optimization therapy (GDHOT) based on major vasopressor and inotropic therapy (SG)
Number of subjects: 40
Study 28054902 — intervention group
Group type: COMPARATOR
Intervention: Standard goal-directed hemodynamic optimization therapy (GDHOT) (CG)
Number of subjects: 40
Study 28054902 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel GDHOT (SG)
Number of subjects: 40